AB0767 OUTCOMES OF SARS-COV-2 INFECTION IN PATIENTS WITH ASSOCIATED ANCA VASCULITIS. DATA FROM THE NATIONAL SAR-COVID REGISTRY
Authors: J. A. Brigante, C. A. Isnardi, D. Emili, V. Saurit, Y. Tissera, M. E. D’Angelo, I. Petkovic, C. Pisoni, R. Quintana, R. Baez, S. Ornella, V. V. Castro Coello, M. Pera, M. Haye, D. A. Pereira, G. Berbotto, C. G. Alonso, C. Gobbi, A. A. Reyes, P. Alba, E. Velozo, M. J. Gamba, R. Tanten, M. Severina, D. Zelaya, G. Alle, A. K. Cogo, R. Nieto, C. Asnal, J. A. Albiero, M. Cosatti, J. Villafañe, F. Maldonado, G. Pons-Estel
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Systemic vasculitis are rare autoimmune diseases that can lead to multiple organs and systems involvement. ANCA-associated vasculitis presents characteristics that differentiate them from other vasculitides. There is evidence that infection by (SARS-CoV-2) impacts differently in patients with various underlying diseases and different comorbidities, even generating differences in the morbidity and mortality of the viral infection. <h3>Objectives</h3> To describe the clinical characteristics and outcomes of SARS-CoV-2 infection in patients with systemic vasculitis. <h3>Methods</h3> Observational, multicenter, cross-sectional analytical study in patients 18 or older diagnosed with systemic vasculitis with confirmed SARS-CoV-2 infection (RT-PCR or serology) included in the SAR-COVID registry. Patients were evaluated from July 2020 to February 2022. Patients diagnosed with ANCA-associated vasculitis (AAV), other systemic vasculitides (Giant cell arteritis, Takayasu), and a control group of patients with other rheumatological diseases matched by age, sex, comorbidities, and date of SARS-CoV-2 infection. The survival curve of the groups was studied by Kaplan-Meier and compared through the Log-Rank Test. A Cox regression model will be performed to adjust survival for different variables (sex, age, treatments for underlying disease, treatments for viral infection, smoking, obesity, d-dimer level, and disease activity). <h3>Results</h3> A total of 282 out of 2694 patients in the SAR-COVID registry were included, 57.4% women with a mean age of 55.7 years (SD 14.1). Fifty-four patients in the AAV group, 32 in the other vasculitis group, and 196 controls were studied. In 51.1% of the cases, one or more comorbidities were observed. We found caucasian ethnicity at 50.7%, mestizo at 39.7%, and other ethnic groups at 9.6%. PCR made the diagnosis of COVID-19 in 81.2% of the cases. The controls had treatment with corticosteroids before the onset of symptoms in 30.1% of the cases, while 64.8% and 68.8% in the AAV group and other vasculitides, respectively (p &lt; 0.001). Hospitalization was required in 53.7% of the AAV group, 37.5% in other vasculitides, and 26.2% in the control group. 5.6% of patients in the control group presented acute respiratory distress syndrome (ARDS), 15.6% in the other vasculitis group, and 22.2% in the AAV group (p&lt;0.001), requiring invasive mechanical ventilation in 13% of the control group. 33.3% of the other vasculitis group and 57% of the patients in the AAV group (p&lt;0.001) Complete recovery was observed in 82.3% of patients in the control group, 75% in the other vasculitis group, and 63% in the AAV group. We observed that 5.7% of the patients in the control group died from COVID-19, 9.4% from other vasculitides, and 27.8% in the AAV group (p&lt;0.001). We found a lower survival in the AAV group compared to the control group (p &lt;0.005). In the multivariate Cox regression model, we can see that older age (HR:1.05 IC95% 1.01-1.09 p=0.01), BMI&gt;40 (HR:13.2 IC95% 2.1-83.2 p=0.01), and high activity of the underlying disease (HR:16 95% CI 3.7-69.4 p&lt;0.005) were associated with lower survival. <h3>Conclusion</h3> In conclusion, we can mention that patients diagnosed with AAV presented a worse evolution of the disease caused by SARS-CoV-2 with a more frequent requirement for invasive mechanical ventilation. Likewise, these patients showed lower survival compared to other autoimmune diseases. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Jorge Alejandro Brigante Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Carolina Ayelen Isnardi Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Daiana Emili Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Veronica Saurit Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Yohana Tissera Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Maria Eugenia D´ angelo Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Ingrid Petkovic Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Cecilia Pisoni Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Rosana Quintana Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Roberto Baez Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Sofia Ornella Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Vanessa Viviana Castro Coello Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Mariana Pera Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Maria Haye Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Dora Aida Pereira Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Guillermo Berbotto Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Carla G Alonso Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Carla Gobbi Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Alvaro Andres Reyes Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Paula Alba Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Edson Velozo Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., María Julieta Gamba Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Romina Tanten Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., María Severina Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., David Zelaya Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Gelsomina Alle Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Adriana Karina Cogo Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Romina Nieto Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., CECILIA ASNAL Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Juan A Albiero Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Micaela Cosatti Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Jaime Villafañe Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Federico Maldonado Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database., Guillermo Pons-Estel Grant/research support from: Grant/research support from: SAR-COVID is a multisponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them. participated or infuenced the development of the project, data collection, analysis, interpretation, or. writing the report. They do not have access to the information collected in the database.